AXL1717: Interim Phase I/II data

Interim data from 35 patients in the Phase I portion of the ongoing, open-label, dose-escalation,

Read the full 151 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE